Phylex Biosciences

is a next-generation vaccine company uniquely located at
the crossroads of information technology and biotechnology.

We are developing the first universal complement SARS-CoV-2 mRNA vaccine. Our vaccine is designed to protect against all variants now prevalent worldwide, including the XBB.1.5, XBB.1.16 and EG.5 variants, all responsible for increased transmissibility of COVID-19 and resistance to current vaccines. Our vaccine complements the limited immunity provided by first and second generation vaccines and breakthrough infections and counters immune imprinting which is limiting the efficacy of all current vaccines. Moreover our vaccine is also designed to protect against viral dissemination and the associated neurological and psychological symptoms of long COVID syndrome.